scholarly journals Is There Any Reason Not to Perform Standard Laparoscopic Total Mesorectal Excision?

2017 ◽  
Vol 30 (05) ◽  
pp. 333-338 ◽  
Author(s):  
Zaher Lakkis ◽  
Yves Panis

AbstractThe curative treatment of locally advanced rectal cancer is currently based on chemoradiotherapy and total mesorectal excision (TME). Laparoscopy has developed considerably because of obvious clinical benefits such as reduced pain and shorter hospital stay. Recently, several prospective randomized clinical trials with long-term follow-up have showed that laparoscopy is noninferior to laparotomy with the same oncologic outcomes in terms of survival and local control rate. However, laparoscopic TME remains a challenging procedure requiring a high level of expertise and a long learning curve to ensure an adequate and safe resection. The only relative contraindication of laparoscopic rectal surgery is T4 rectal cancer extended beyond the plane of TME. In this situation, it is reasonable to consider an open resection to avoid an uncomplete resection. In obese and elderly patients, laparoscopic TME also provides the same benefits as in nonobese and younger patients but may be more difficult to achieve. This review summarizes current knowledge on the place of laparoscopic TME in the treatment of rectal cancer.

Author(s):  
Narendra Pandit ◽  
Kunal Bikram Deo ◽  
Sujan Gautam ◽  
Tek Narayan Yadav ◽  
Awaj Kafle ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-9
Author(s):  
Yanwu Sun ◽  
Pan Chi

Aims.To evaluate the impact of body mass index (BMI) on the surgical outcome of laparoscopic total mesorectal excision (laTME) for locally advanced rectal cancer (LARC, clinically staged as UICC stage II/III) after neoadjuvant chemoradiotherapy (nCRT).Methods.312 LARC patients undergoing laTME after nCRT were divided into nonobese (BMI < 25.0 kg/m2,n=249) and obese (BMI ≥ 25.0 kg/m2,n=63) groups. Preoperative radiotherapy was delivered in 45–50.4 Gy/25f, 5 days/week, and concurrent chemotherapy using FOLFOX or CapeOX. Technical feasibility, postoperative and oncological outcome were compared between groups.Results.Obese patients had significantly longer operative time (P=0.004). There was no significant difference regarding estimated blood loss, conversion, postoperative recovery, and morbidities. Multivariate analysis demonstrated that higher ASA score and abdominoperineal resection were risk factors for postoperative complications and diverting stoma was a protective factor. The length of resection margin, circumferential resection margin involvement, and number of lymph node retrieved were comparable. With a median follow-up time of 55 months (ranging 20–102 months), oncological outcome was comparable in terms of overall survival, local recurrence, and distant metastasis.Conclusions.Obesity does not affect surgical or oncological outcome of laTME after nCRT. LaTME may be feasible and safe to obese LARC patients after nCRT in a specialized center.


Sign in / Sign up

Export Citation Format

Share Document